DDInter1765 DDInter782
Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Teniposide {u} (Compound) resembles {v} (Compound) Podofilox
Teniposide {u} (Compound) treats {v} (Disease) lung cancer
Teniposide {u} (Compound) binds {v} (Gene) CYP2C9
Teniposide {u} (Compound) upregulates {v} (Gene) EDEM1
Teniposide {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Teniposide {u} (Compound) downregulates {v} (Gene) CLTC
Teniposide {u} (Compound) causes {v} (Side Effect) Flushing
Teniposide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delavirdine
Teniposide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Grepafloxacin
Teniposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levodopa
Teniposide (Compound) resembles Podofilox (Compound)
Teniposide (Compound) treats lung cancer (Disease)
Teniposide (Compound) binds CYP2C9 (Gene)
Teniposide (Compound) upregulates EDEM1 (Gene)
Teniposide (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Teniposide (Compound) downregulates CLTC (Gene)
Teniposide (Compound) causes Flushing (Side Effect)
Teniposide may cause a minor interaction that can limit clinical effects when taken with Delavirdine
Teniposide may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin
Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Levodopa